AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01973608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB0010445 (0.3 milligram per kilogram [mg/kg])
Description: MSB0010445 will be administered at a single dose of 0.3 mg/kg as intravenous (IV) infusion over approximately 1 hour every 3 weeks (q3w) for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of Stereotactic Body Radiation Therapy (SBRT) to the targeted reference lesion.
Study NCT01973608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB0010445 (1.0 mg/kg)
Description: MSB0010445 will be administered at a single dose of 1.0 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
Study NCT01973608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB0010445 (1.8 mg/kg)
Description: MSB0010445 will be administered at a single dose of 1.8 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
Study NCT01973608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB0010445 (2.4 mg/kg)
Description: MSB0010445 will be administered at a single dose of 2.4 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
Study NCT01973608 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: SBRT will be administered using a dose and schedule recommended based upon the data showing the best abscopal effect using multiple fractions if one site will be targeted subject received 3 fractions (1 per day) of 8 Gray (Gy) each (total: 24 Gy). If the target lesion will be located in the thorax, the maximum total dose administered will be 18 Gy (3 x 6 Gy).
Study NCT02834104 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Study NCT03410589 — intervention group
Intervention type: OTHER
Intervention: Sinlge arm
Description: application of scales for evaluation of sleep, fatigue and quality of life - Observational study
Study NCT00245206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Participant will take aripiprazole. Dosing will be determined by each participant's psychiatrist.
Study NCT00245206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Participant will take olanzapine. Dosing will be determined by each participant's psychiatrist.
Study NCT00245206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Participant will take risperidone. Dosing will be determined by each participant's psychiatrist.
Study NCT02499497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LY2452473
Description: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.
Study NCT00918658 — intervention group
Intervention type: OTHER
Intervention: biologic sample preservation procedure
Description: All specimens will be collected using the Pathology Residual Tissue Procurement.
Study NCT00918658 — intervention group
Intervention type: OTHER
Intervention: immunologic technique
Description: Information about HLA type and immunophenotype of the malignant cells is collected from the patient's medical record.
Study NCT00918658 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Bone marrow aspirates and/or peripheral blood samples are collected and used as target cells in standard cytotoxicity assays, with notch-induced natural killer (N-NK) cells as the effector cells, to determine whether N-NK cells are capable of killing malignant cells and/or non-malignant cells. Receptor-blocking antibodies may be added to determine which NK cell receptors are responsible for malignant cell recognition and killing.
Study NCT01988831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol hydrochloride
Description: This intervention apply to Propranolol group
Study NCT02499497 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants will receive pills containing no active drug.
Study NCT05149963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) for Chronic Loneliness
Description: Participants will receive an average of 12 50-minute sessions of Cognitive Behavioural Therapy (CBT) aiming to reduce their feelings of loneliness
Study NCT04101045 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Oral Glucose Tolerance Test
Description: Each participant consumes a dinner scaled to his/her energy needs which is prepared by the metabolic kitchen. Dinner will be provided beforehand if patient does this portion at home. The participant consumes the first of three doses of D2O. Two additional doses of D20 are given at on day 1 and on day 2. The total D2O given (3 ml per kg of body water) is designed to raise body deuterium levels to 0.3% and is administered as described above to maintain steady state until the end of the study. At the HRU, an IV catheter will be inserted in order to collect blood to assess DNL. Blood draws begin during the fasting state to assess basal rates of DNL and then for six hours after the consumption of a glucose/fructose beverage (75g glucose and 25g fructose ) to assess postprandial rates of DNL. Blood draws will be taken 15 minutes before ingestion of the sugar beverage, then for every half hour for 6 hours.
Study NCT04504942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leronlimab
Description: Drug: Leronlimab 525mg
Study NCT02127034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: oral
Study NCT01988831 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: We use placebo pills alike propranolol commercial pills to ensure blindness of the subjects during the study.
Study NCT03294395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem 1000 MG
Description: single dose 1000mg intramuscular injection
Study NCT02127034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: oral
Study NCT02127034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: oral
Study NCT03294395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin Oral Suspension
Description: single dose 6g oral suspension
Study NCT00955565 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Navigated
Description: Subjects receive receive computer assisted placement of the sacroiliac screws. The computer assisted placement will be performed by using the BrainLab Vector Vision®Trauma Navigation Software. Two approaches will be used, the 2D navigation and 3D navigation.
Study NCT00955565 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: Subjects receive standard fluoroscopic placement of the sacroiliac screw.
Study NCT03593785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8233
Description: Randomized subjects will receive single SC dose of AZD8233 (dose 1, dose 2, dose 3, dose 4 and dose 5) injection.
Study NCT02736513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291
Description: Patients will receive AZD9291 at a dose of 80 mg once daily.
Study NCT02212678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine capsule
Description: N-acetylcysteine capsule
Study NCT02753127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Napabucasin
Description: Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 12 hours (480 mg total daily dose).
Study NCT02753127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Study NCT02753127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Study NCT02753127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Study NCT02753127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Study NCT02753127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Study NCT02753127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study NCT02753127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Study NCT02753127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT02351349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multidisciplinary intervention
Description: multidisciplinary intervention
Study NCT05036200 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulsed dye laser
Description: four pulsed dye laser sessions were administered every eight weeks in the 21 patients
Study NCT00046930 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: 250 μg/m2/day by either intravenous or subcutaneous injection starting day 12, provided marrow aplasia is achieved, through recovery of absolute neutrophil count (ANC) to > 500 cells/μl, sustained for 3 consecutive days. The dose may be rounded to the nearest vial size.
Study NCT00046930 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: 250 μg/m2/day by either intravenous or subcutaneous injection starting day 12, provided marrow aplasia is achieved, through recovery of absolute neutrophil count (ANC) to > 500 cells/μl, sustained for 3 consecutive days. The dose may be rounded to the nearest vial size.
Study NCT00046930 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sargramostim
Description: 5 μg/kg/day by either intravenous or subcutaneous injection starting day 12, provided marrow aplasia is achieved, through recovery of absolute neutrophil count (ANC) to > 500 cells/μl, sustained for 3 consecutive days. The dose may be rounded to the nearest vial size.
Study NCT00046930 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: 5 μg/kg/day by either intravenous or subcutaneous injection starting day 12, provided marrow aplasia is achieved, through recovery of absolute neutrophil count (ANC) to > 500 cells/μl, sustained for 3 consecutive days. The dose may be rounded to the nearest vial size.
Study NCT00046930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine
Description: 100 mg/m²/day by continuous intravenous infusion for 7 days (days 1-7).
Study NCT00046930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 100 mg/m²/day by continuous intravenous infusion for 7 days (days 1-7).
Study NCT00046930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: daunorubicin hydrochloride
Description: 45 mg/m²/day by 10 - 15 minute intravenous infusion for 3 days (days 1, 2, and 3).
Study NCT00046930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: 45 mg/m²/day by 10 - 15 minute intravenous infusion for 3 days (days 1, 2, and 3).
Study NCT00046930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zosuquidar trihydrochloride
Description: Zosuquidar 550 mg/day by continuous intravenous infusion through a central venous catheter over approximately 6 hours on days 1, 2, and 3.~The infusion will begin approximately one hour prior to daunorubicin on days 1, 2 and 3.
Study NCT00046930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo 550 mg/day by continuous intravenous infusion through a central venous catheter over approximately 6 hours on days 1, 2, and 3.~The infusion will begin approximately one hour prior to daunorubicin on days 1, 2 and 3. Placebo consisted of a 1:1000 dilution of Infuvite, appropriately colored.
Study NCT00596141 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OroScience Topical Oral Wound Emulsion
Description: TOWE will be applied 3 times daily for a period of 7 days by the patient dispensing TOWE into a disposable dental tray and placing the dental tray over the dental arch and covering the surgical site.
Study NCT03632603 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: No intervention
Description: No intervention during study period.
Study NCT03632603 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: No intervention during study period.
Study NCT02060032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.2% Atorvastatin local drug delivery
Study NCT02060032 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 1.2% simvastatin local drug delivery
Study NCT02060032 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo local drug delivery
Study NCT04326660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCOPE-Chinese Women
Description: SCOPE-Chinese Women is a smart-phone based intervention that includes a Fitbit tracking device to monitor daily activity, 12-weeks of educational modules delivered by WeChat, and Bi-weekly messages that encourage positive behavioral change. The data will be examined by the research team to assess efficacy of the intervention.
Study NCT00460590 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA 85A
Description: ID vaccine
Study NCT02151331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: External Facilitation
Description: Non-responding sites randomized to receive external facilitation
Study NCT02151331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: External + Internal Facilitation
Description: Non-responding sites randomized to receive both internal and external facilitation
Study NCT01459991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walnut
Description: Participants will consume 1 ounce walnuts daily and follow a Mediterranean style diet.
Study NCT01459991 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MyPyramid
Description: Participants will follow a USDA MyPyramid style diet for lactating moms.
Study NCT01519674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: BIAsp 30 will be injected subcutaneously (under the skin) twice daily. Individually adjusted dose.
Study NCT03294395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin Sulfate, Injectable
Description: single dose 5mg/kg (maximum 400mg) intramuscular injection
Study NCT01519674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: BIAsp 30 will be injected subcutaneously (under the skin) once daily. Individually adjusted dose.
Study NCT01519674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: Subjects will continue on their pre-trial sitagliptin treatment.
Study NCT01519674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Subjects will continue on their pre-trial metformin treatment.
Study NCT04738591 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIABE-TEXT
Description: Participants will receive daily (from monday to friday) text messages in their mobile phones during three months.
Study NCT01610596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Halobetasol Propionate Lotion 0.05%
Description: Apply twice daily for 1-2 weeks, not to exceed 50 grams per week
Study NCT01610596 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00090415 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive behavioral therapy
Description: Participants will undergo a magnetic resonance imaging (MRI) scan and will complete various activities to determine brain functioning. In addition, children with autism will take part in intensive behavioral therapy at least 4 hours every day for the duration of the study.
Study NCT03294395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: single dose 500mg intramuscular injection
Study NCT01005914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Day 1- 3: 300 m g/m2 IV over 2-3 hours every 12 hours for 6 doses plus mesna 600 mg/ m2 /day continuous infusion Days 1-3
Study NCT01931878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: incobotulinumtoxinA
Description: The subject may be randomly assigned to receive incobotulinum toxinA (Xeomin) , a neurotoxin Which is approved for use by the FDA for certain conditions. This study has a double blind cross over design. Cross over means that you will have two sets of injections. If the first set of injections is Xeomin, the second injections after a three month interval will be the inactive placebo. Double blind means neither the investigators nor the subject knows which one of the two (Xeomin or placebo) is received with the first or second injections.
Study NCT01931878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subject may be randomly assigned to receive Placebo which is an inactive test substance which has no active ingredient. In this protocol we use sterile salt water as placebo.This study has a double blind cross over design. Cross over means that you will have two sets of injections. If the first set of injections is placebo, the second injections after a three month interval will be active study drug. Double blind means neither the investigators nor the subject knows which one of the two (Xeomin or placebo) is received with the first or second injections.
Study NCT03190811 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 plus DC-CIK
Description: Anti-PD-1 antibody treatment: Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.~DC-CIK Immunotherapy: Mononuclear cells were collected aseptically with blood cell separator composition apheresis, and cultured DC-CIK cells for 10-14 days. Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of DC-CIK Immunotherapy along with 4 dosage of anti-PD-1 antibody treatment. If the evaluation of the treatment is partial response or stable disease, additional cycles were eligible.
Study NCT03190811 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Anti-PD-1 alone
Description: Anti-PD-1 antibody treatment: Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.
Study NCT01675648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lofexidine
Study NCT01675648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam
Study NCT01675648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Lofexidine
Study NCT01675648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Diazepam
Study NCT02285088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GBT440
Description: GBT440 will be administered as oral capsules
Study NCT02285088 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered as oral capsules
Study NCT01028482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: group A- sertraline 50-100 mg/day and weekly psychotherapy for 3 months~group B- weekly psychotherapy- for 3 months~group C- sertraline 50-100 mg/day-for 3 months
Study NCT01028482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01028482 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: psychotherapy
Description: psychotherapy
Study NCT01028482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychotherapy
Description: psychotherapy
Study NCT00663026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bapineuzumab
Description: 5 mg bapineuzumab subcutaneous injection once per week for 6 months
Study NCT00663026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bapineuzumab
Description: 10 mg bapineuzumab subcutaneous injection once per week for 6 months
Study NCT00663026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo subcutaneous injection once per week for 6 months
Study NCT03685422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Before surgery, consented patients are given a Virtual Reality headset with pre-installed relaxation apps to choose a preferred scenario. Patient will be asked on their satisfaction on the VR experience after the intervention. Visual analog scale-anxiety (VAS-A), Spielberger State-Trait Anxiety Inventory (STAI) and EQ-5D-3L questionnaires will be conducted during this period.